Last reviewed · How we verify
innohep®
Innohep is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.
Innohep is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin. Used for Prophylaxis of deep vein thrombosis (DVT) in patients undergoing general or orthopedic surgery, Treatment of acute deep vein thrombosis and pulmonary embolism, Prophylaxis of thromboembolism in patients with acute myocardial infarction.
At a glance
| Generic name | innohep® |
|---|---|
| Also known as | Tinzaparin sodium, Tinzaparin |
| Sponsor | LEO Pharma |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Antithrombin III (enhancer); Factor Xa and Thrombin (indirect targets) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Innohep (tinzaparin sodium) is a low-molecular-weight heparin (LMWH) derived from porcine intestinal mucosa. It potentiates the inhibition of coagulation factors, particularly factor Xa and thrombin, through its interaction with antithrombin III. This prevents thrombus formation and is used for thromboprophylaxis and treatment of venous thromboembolism.
Approved indications
- Prophylaxis of deep vein thrombosis (DVT) in patients undergoing general or orthopedic surgery
- Treatment of acute deep vein thrombosis and pulmonary embolism
- Prophylaxis of thromboembolism in patients with acute myocardial infarction
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated liver enzymes
Key clinical trials
- Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis (PHASE4)
- Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer (PHASE2)
- Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer (PHASE3)
- Therapeutic Anticoagulation Strategy for Acute Chest Syndrome (PHASE3)
- The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer (PHASE3)
- A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study (PHASE2)
- Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort (PHASE2)
- Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- innohep® CI brief — competitive landscape report
- innohep® updates RSS · CI watch RSS
- LEO Pharma portfolio CI